EGM
TSHA icon

Engineers Gate Manager’s Taysha Gene Therapies TSHA Stock Holding History

Engineers Gate Manager’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-53,483
Closed -$175K – 2556
2025
Q3 		$175K Sell
53,483
-11,134
-17% -$31.5K ﹤0.01% 1933
2025
Q2 		$149K Buy
+64,617
New +$140K ﹤0.01% 1942
2025
Q1 		– Sell
-35,808
Closed -$61.9K – 2591
2024
Q4 		$61.9K Buy
+35,808
New +$74.3K ﹤0.01% 2054
2024
Q2 		– Sell
-110,992
Closed -$319K – 2244
2024
Q1 		$319K Buy
110,992
+89,296
+412% +$186K 0.01% 1431
2023
Q4 		$38.4K Buy
+21,696
New +$43.3K ﹤0.01% 1868
2023
Q3 		– Sell
-13,650
Closed -$9.02K – 2091
2023
Q2 		$9.02K Hold
13,650
– – ﹤0.01% 1689
2023
Q1 		$10.9K Buy
+13,650
New +$17.6K ﹤0.01% 1598

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Engineers Gate Manager's TSHA Position: Q4 2025 in Review

Engineers Gate Manager sold out of Taysha Gene Therapies (TSHA) in Q4 2025, closing a stake of 53,483 shares — an estimated $175K sold.

Engineers Gate Manager first reported a position in TSHA in Q1 2023 and held it in 7 quarters. The position peaked at $319K in Q1 2024. 195 funds tracked by Wall St. Rank hold TSHA as of Q4 2025.

  • Engineers Gate Manager reported no remaining Taysha Gene Therapies position as of Q4 2025 after selling out during the quarter.
  • Engineers Gate Manager sold 53,483 Taysha Gene Therapies shares in Q4 2025, an estimated $175K.
  • Engineers Gate Manager first reported a position in Taysha Gene Therapies in Q1 2023 and held it in 7 quarters.
  • Engineers Gate Manager's Taysha Gene Therapies position peaked at $319K in Q1 2024.
  • 195 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2025.

Based on Engineers Gate Manager's 13F filing for Q4 2025, filed 17 Feb 2026.